| HUMAW Stock | | | USD 1.50 0.09 5.66% |
Founder
Juliana Blum is CoFounder Advisor of Humacyte
| Address | 2525 East North Carolina Highway 54, Durham, NC, United States, 27713 |
| Phone | 919 313 9633 |
| Web | https://www.humacyte.com |
Humacyte Management Efficiency
The company has return on total asset
(ROA) of
(0.5323) % which means that it has lost $0.5323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(8.5081) %, meaning that it generated substantial loss on money invested by shareholders. Humacyte's management efficiency ratios could be used to measure how well Humacyte manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to climb to -0.82 in 2024.
Return On Capital Employed is likely to drop to -0.96 in 2024. At this time, Humacyte's
Total Assets are fairly stable compared to the past year.
Non Current Assets Total is likely to climb to about 46.6
M in 2024, despite the fact that
Return On Tangible Assets are likely to grow to
(0.82).
Humacyte (HUMAW) is traded on NASDAQ Exchange in USA. It is located in 2525 East North Carolina Highway 54, Durham, NC, United States, 27713 and employs 183 people. Humacyte is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Humacyte Leadership Team
Elected by the shareholders, the Humacyte's board of directors comprises two types of representatives: Humacyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Humacyte. The board's role is to monitor Humacyte's management team and ensure that shareholders' interests are well served. Humacyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Humacyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juliana Blum, CoFounder Advisor | |
| Harold Alterson, Senior Quality | |
| MS MS, Chief Officer | |
| Sabrina Osborne, Executive People | |
| Kiernan MD, Chief Officer | |
| Dale Sander, Chief CFO | |
| William Scheessele, Chief Officer | |
| Yang MD, Chief Officer | |
| B Scheessele, Chief Officer | |
| Shamik MD, Chief Officer | |
| SPHR GPHR, Chief Officer | |
| Heather Prichard, Chief Officer | |
Humacyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Humacyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to
measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to
predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.